创新药发展再迎政策利好 医保数据“导航”研发

Core Insights - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, focusing on a comprehensive support system from research and development to clinical application [1][3][4] Group 1: Policy Measures - The measures include establishing a commercial health insurance directory for innovative drugs and utilizing healthcare data for drug research and development, addressing industry challenges such as payment bottlenecks and homogenized competition [1][2][3] - A total of 16 initiatives across five areas were proposed to enhance support for innovative drug development, including encouraging clinical application and improving multi-channel payment capabilities [3][4] Group 2: Market Dynamics - The approval of Class 1 innovative drugs in China has significantly increased, with 48 drugs expected to be approved in 2024, a fivefold increase from 2018 [3] - The commercial health insurance market is growing rapidly, with over 95% fund utilization in basic medical insurance compared to a lower level in commercial health insurance, indicating room for development [2] Group 3: Payment Mechanisms - The dynamic adjustment mechanism for the medical insurance directory has improved, with the proportion of new drugs approved within the same year rising from 32% in 2019 to 98% in 2024 [5] - The time for new drugs to be included in the medical insurance directory has decreased from approximately five years to around one year, with about 80% of innovative drugs being included within two years of market approval [5] Group 4: International Expansion - Chinese innovative drugs are increasingly entering international markets, with over 90 overseas licensing transactions completed in 2024, totaling over $50 billion [8] - The measures encourage the establishment of global trading platforms for innovative drugs, particularly targeting Southeast Asia and Central Asia [8] Group 5: Pricing Strategies - The current pricing of innovative drugs in China is considered low globally, with discussions on implementing strict price confidentiality mechanisms for drugs in the commercial health insurance directory [9] - The policy aims to create a closed-loop system supporting the high-quality development of innovative drugs, facilitating China's transition from a generic drug powerhouse to an innovative drug leader [9]